Actinium Pharmaceuticals, Inc. (NYSE:ATNM) Given Average Recommendation of “Moderate Buy” by Brokerages

Actinium Pharmaceuticals, Inc. (NYSE:ATNM) has been assigned an average rating of “Moderate Buy” from the five analysts that are currently covering the firm, MarketBeat reports. One research analyst has rated the stock with a hold rating and four have assigned a buy rating to the company. The average 1-year target price among brokerages that have issued a report on the stock in the last year is $7.40.

A number of research firms have recently commented on ATNM. StockNews.com downgraded shares of Actinium Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Monday, November 11th. Stephens reiterated an “overweight” rating and set a $5.00 target price on shares of Actinium Pharmaceuticals in a report on Tuesday, November 19th. Finally, HC Wainwright restated a “buy” rating and issued a $4.00 price target on shares of Actinium Pharmaceuticals in a research note on Friday, November 15th.

Actinium Pharmaceuticals Trading Down 3.7 %

NYSE:ATNM opened at $1.29 on Friday. The firm has a market cap of $40.25 million, a P/E ratio of -0.93 and a beta of 0.12. Actinium Pharmaceuticals has a twelve month low of $1.10 and a twelve month high of $10.24. The business’s 50 day moving average price is $1.31.

Institutional Trading of Actinium Pharmaceuticals

Several institutional investors and hedge funds have recently bought and sold shares of the business. Los Angeles Capital Management LLC bought a new stake in shares of Actinium Pharmaceuticals during the 3rd quarter worth about $322,000. XTX Topco Ltd acquired a new stake in Actinium Pharmaceuticals during the third quarter worth approximately $268,000. Marshall Wace LLP boosted its holdings in shares of Actinium Pharmaceuticals by 67.9% during the second quarter. Marshall Wace LLP now owns 256,026 shares of the company’s stock worth $1,895,000 after acquiring an additional 103,557 shares during the period. Wellington Management Group LLP acquired a new position in shares of Actinium Pharmaceuticals in the third quarter valued at approximately $112,000. Finally, Squarepoint Ops LLC bought a new position in shares of Actinium Pharmaceuticals during the second quarter worth approximately $356,000. Institutional investors own 27.50% of the company’s stock.

Actinium Pharmaceuticals Company Profile

Actinium Pharmaceuticals, Inc develops antibody radiation conjugates and other targeted radiotherapies intended to improve outcomes for people who have failed existing oncology therapies. Its Iomab-B is an induction and conditioning agent prior to bone marrow transplant in patients with relapsed and refractory acute myeloid leukemia (r/r AML).